GLP-1 medicines and drug interactions — what UK SmPCs say

What the mechanism of interaction is

GLP-1 receptor agonists, including semaglutide, tirzepatide and liraglutide, are peptide molecules that are not substantially metabolised through the liver's cytochrome P450 enzyme pathways that underpin many classic drug-drug interactions. This means GLP-1 medicines generally do not alter the blood levels of other drugs through metabolic competition in the way, for example, some antifungal or antiretroviral medicines do. The interactions of most practical relevance instead arise from two indirect mechanisms: delayed gastric emptying affecting the absorption timing of co-administered oral medicines, and the physiological consequences of weight loss and improved glucose control affecting dosing requirements for other medicines, particularly glucose-lowering and anticoagulant therapies.

The classes with the most evidence for meaningful interaction

Four medicine classes are most frequently discussed in pharmacology literature and prescribing guidance in connection with GLP-1 therapy. Levothyroxine, because its absorption depends on consistent gastric transit and timing relative to food. Warfarin, because INR stability is sensitive to the dietary and weight changes that accompany GLP-1 therapy, independent of any direct drug-drug interaction. Insulin and sulfonylureas, because combining them with a GLP-1 medicine improves overall glycaemic control and can precipitate hypoglycaemia unless doses are reviewed — this is the interaction with the clearest clinical evidence base and the most direct prescribing implication. Oral contraceptives, where the concern relates primarily to gastrointestinal side effects reducing absorption rather than a direct pharmacokinetic interaction, except in specific circumstances addressed in individual product labelling.

What UK SmPCs say

SmPC interaction sections for licensed GLP-1 medicines generally state that no clinically relevant pharmacokinetic interactions have been identified with most commonly co-administered medicines in dedicated interaction studies, reflecting the absence of a major cytochrome P450 interaction pathway. Where a specific interaction consideration is flagged, it typically relates to oral medicines with a narrow therapeutic index or strict absorption requirements — levothyroxine and warfarin fall into this category by virtue of their own pharmacological profile rather than because of a specific documented GLP-1 interaction study finding a problem. For oral semaglutide specifically, the SmPC includes its own formulation-specific administration instructions regarding co-administered oral medicines, reflecting oral semaglutide's own strict absorption requirements. The current SmPC for the specific product prescribed is the definitive source, and wording can differ meaningfully between products and molecules.

What clinicians and patients should watch

For people on levothyroxine, warfarin, insulin, sulfonylureas, DOACs or oral contraceptives who are starting a GLP-1 medicine, the practical considerations are monitoring-based rather than requiring a fixed interaction-avoidance schedule: thyroid function testing for levothyroxine, INR monitoring for warfarin, blood glucose monitoring and dose review for insulin or sulfonylureas, and attentiveness to gastrointestinal side effects for oral contraceptive users. See hypoglycaemia risk by drug class for the specific insulin and sulfonylurea interaction in more detail, and GLP-1 gastrointestinal adverse events for the broader tolerability picture that underpins several of these indirect interaction mechanisms. None of this page's content substitutes for a pharmacist or prescriber review of an individual's full medication list.

What the evidence does not establish

Dedicated head-to-head interaction trials are not available for every possible medicine combination discussed here — much of the levothyroxine and warfarin discussion, in particular, rests on pharmacological plausibility and monitoring-based clinical experience rather than large controlled interaction studies specific to GLP-1 co-administration. The absence of a documented major interaction in an SmPC reflects the interaction studies that have been conducted to date, not proof that no interaction of any kind exists for every individual. Population-level interaction study data also do not capture every individual variation in gut transit time, existing gastrointestinal disease, polypharmacy burden or organ function that could, in principle, alter how a specific person absorbs or responds to a co-administered medicine. This page does not provide dosing schedules, specific timing recommendations, or a substitute for individualised monitoring plans agreed with a prescriber or pharmacist familiar with a person's full medication history.

Frequently asked questions

Do GLP-1 medicines interact with other drugs?

GLP-1 receptor agonists are not extensively metabolised by the liver's cytochrome P450 enzyme system, which means they largely avoid the classic pharmacokinetic interaction pathway that causes many drug-drug interactions. However, their delayed-gastric-emptying effect can alter how quickly other oral medicines are absorbed, and their weight-loss and appetite effects can change dosing requirements for some concurrent medicines indirectly. This page summarises the classes with the most-discussed interaction potential; it does not replace a pharmacist or prescriber medication review.

Why does delayed gastric emptying matter for other medicines?

Many oral medicines are absorbed primarily in the small intestine, so how quickly they leave the stomach can affect how quickly — though not necessarily how completely — they are absorbed. For medicines where the speed of absorption matters clinically, such as those requiring a specific empty-stomach timing window, delayed gastric emptying is a theoretically relevant consideration. For most medicines, a change in absorption speed without a change in total absorbed amount has limited clinical significance, but for a small number of narrow-therapeutic-index or timing-sensitive medicines it is worth specific attention from a prescriber or pharmacist.

Does semaglutide affect levothyroxine absorption?

Levothyroxine requires consistent, reliable absorption and is typically taken on an empty stomach with specific timing relative to food for this reason. Delayed gastric emptying from a GLP-1 medicine is a plausible mechanism for altered levothyroxine absorption timing, and this is a recognised theoretical interaction discussed in pharmacology literature, though robust head-to-head interaction trial data specific to GLP-1 co-administration are limited. In practice, thyroid function is monitored by blood test in people on levothyroxine, which provides a practical way to detect any clinically meaningful change in absorption over time. Anyone on both medicines should discuss monitoring frequency with their prescriber rather than assuming no interaction exists.

Does a GLP-1 medicine affect warfarin and INR?

There is no established direct pharmacokinetic interaction between GLP-1 receptor agonists and warfarin at the metabolic level, but warfarin is a narrow-therapeutic-index medicine where INR (International Normalised Ratio) is sensitive to changes in diet, weight, and gastrointestinal absorption generally. Significant weight loss and appetite or dietary changes — both expected effects of GLP-1 therapy — can independently influence vitamin K intake and INR stability. For this reason, more frequent INR monitoring during initiation and dose titration of a GLP-1 medicine is a reasonable and commonly applied precaution in people on warfarin, agreed with the anticoagulation clinic or prescriber managing warfarin dosing.

Do GLP-1 medicines reduce the effectiveness of the contraceptive pill?

For semaglutide specifically, the product SmPC states there is no clinically relevant effect on oral contraceptive pharmacokinetics based on dedicated interaction study data. However, gastrointestinal side effects such as vomiting or severe diarrhoea — which can occur with any GLP-1 medicine, particularly during titration — can independently reduce oral contraceptive absorption and effectiveness, as is the case with any oral medicine during a vomiting or diarrhoeal illness. Some regulatory discussion has also focused on higher-BMI subgroups (for example around BMI 40 and above), reflecting broader pharmacokinetic questions in that population rather than a semaglutide-specific contraceptive interaction. Anyone relying on oral contraception should discuss suitable contraceptive strategy with their prescriber, particularly if experiencing significant gastrointestinal side effects.

Is there a hypoglycaemia risk when combining a GLP-1 medicine with insulin or sulfonylureas?

Yes — this is one of the more clinically significant interaction considerations in this class. GLP-1 receptor agonists alone carry a low intrinsic hypoglycaemia risk because their glucose-lowering effect is glucose-dependent, but insulin and sulfonylureas both carry an independent, non-glucose-dependent hypoglycaemia risk. When a GLP-1 medicine is added to an existing insulin or sulfonylurea regimen, overall glucose control typically improves, which increases the likelihood of hypoglycaemia unless the insulin or sulfonylurea dose is reviewed. This is a well-established prescribing consideration, and dose adjustment of the insulin or sulfonylurea — not the GLP-1 medicine — is the typical clinical response, made by the prescriber managing diabetes therapy.

Do GLP-1 medicines affect blood-thinning drugs like DOACs (apixaban, rivaroxaban)?

Direct oral anticoagulants (DOACs) do not require the same dietary monitoring as warfarin, and there is no established major pharmacokinetic interaction between GLP-1 medicines and DOACs at the metabolic level. Delayed gastric emptying is a theoretical consideration for absorption timing of any oral medicine, including DOACs, but DOACs generally have a wider therapeutic window than warfarin, making absorption-timing changes less likely to be clinically significant. This remains a general absorption consideration worth being aware of rather than an established, quantified interaction.

Should I take other tablets at a different time of day because of my GLP-1 medicine?

This is a practical medicines-management question best answered by a pharmacist or prescriber who can review your full medication list, since the answer depends on which specific medicines you take, their absorption requirements, and your GLP-1 dose and formulation. This page does not provide individual timing schedules.

Are interactions different for oral semaglutide (Rybelsus) compared with injectable forms?

Oral semaglutide has specific absorption requirements of its own — it must be taken on an empty stomach with a small amount of water, and other oral medicines should generally be taken a set interval afterwards, per the product's own administration instructions, because co-administration with food or other substances can reduce its own absorption. This is an additional layer of interaction consideration specific to the oral formulation, separate from the general gastric-emptying discussion that applies to all GLP-1 medicines regardless of route. The current Rybelsus SmPC administration instructions are the definitive reference for this formulation-specific consideration.

Who should review my medicines before or during GLP-1 therapy?

A full medication review by the prescriber initiating GLP-1 therapy, or by a pharmacist, is the appropriate way to identify medicine-specific interaction considerations relevant to your own regimen. This page describes general interaction classes reported in pharmacology literature and product labelling; it is not a substitute for a review of your specific medicines.